24 Nov 2023
Global Health EDCTP3 Joint Undertaking becomes autonomous and starts new implementation phase
On 23 November 2023, the Global Health EDCTP3 Joint Undertaking acquired financial autonomy from the European Commission to implement its own budget.
Established on 30 November 2021, the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU) is the EU’s landmark clinical trials partnership with Africa, working to deliver new solutions to reduce the burden of infectious diseases in sub-Saharan Africa and to strengthen research capacities to prepare and respond to re-emerging infectious diseases. It follows the successful EDCTP and EDCTP2 programmes, which have supported clinical research and capacity building in the field of infectious diseases since 2003 and have contributed to the development of key health interventions, including the R21/Matrix-M vaccine recently recommended by the World Health Organisation (WHO) for the prevention of malaria in children.
The Global Health EDCTP3 JU now enters a new implementation phase, under which it will be independent to manage its own decisions and its (up to) €1.6 billion budget, streamlining and simplifying operations. Under the steer of Dr Michael Makanga, Executive Director, Global Health EDCTP3 JU is expected to publish its 2024 Work Programme with all research funding opportunities for that year in the first quarter of 2024.